Transplantation with allogenic bone marrow from a donor with systemic lupus erythematosus (SLE): successful outcome in the recipient and induction of an SLE flare in the donor

TitleTransplantation with allogenic bone marrow from a donor with systemic lupus erythematosus (SLE): successful outcome in the recipient and induction of an SLE flare in the donor
Publication TypeJournal Article
Year of Publication1996
AuthorsSturfelt G, Lenhoff S, Sallerfors B, Nived O, Truedsson L, Sjoholm AG
JournalAnn Rheum Dis
Volume55
Issue9
Pagination638 - 41
Date PublishedSep
ISSN0003-4967 (Print) 0003-4967 (Linking)
Accession Number8882135
Keywords*Tissue Donors, Adult, Autoantibodies / metabolism, Bone Marrow Transplantation / *immunology, Complement C1q / immunology, Graft vs Host Disease / immunology, Humans, Leukemia, Myeloid, Acute / therapy, Lupus Erythematosus, Systemic / *immunology, Male, Middle Aged, Transplantation, Homologous
Abstract

OBJECTIVE: To investigate the transfer of autoimmunity by allogenic bone marrow transplantation. METHODS: Bone marrow transplantation was performed in a 43 years old man with acute myeloid leukaemia (AML) in remission. The donor was his HLA identical brother who had a mild systemic lupus erythematosus (SLE). Autoantibodies, including antinuclear, anti-C1q, and anticardiolipin antibodies, were measured before and after transplantation. RESULTS: Transient mild graft versus host disease (GvHD) developed in the recipient in the weeks following transplantation. The donor had persistently high concentrations of anti-C1q antibodies to the collagenous region of the complement component C1q. Three months after transplantation the recipient developed antiC1q antibodies that persisted for two months. No other autoantibodies and no SLE-like manifestations appeared. Chronic GVHD started five months posttransplant and responded to intensified immunosuppressive treatment. Three years post-transplant the patient was in unmaintained remission. Within a few weeks after bone marrow donation the donor's disease was exacerbated with development of severe pulmonary alveolitis which required treatment with cyclophosphamide. CONCLUSIONS: When bone marrow transplantation was performed in a patient with AML with bone marrow from an HLA identical brother who had SLE, no evidence of transfer of disease was obtained. However, the recipient temporarily produced anti-C1q antibodies which was a characteristic feature of the donor's SLE and was probably produced by the transplant. The flare of the donor's SLE might be related to the bone marrow tap.

Notify Library Reference ID1491

Related Incidents